Drug-induced hepatotoxicity of anti-tuberculosis drugs and their serum levels (Q35028452)

5 August 2017

title

Drug-induced hepatotoxicity of anti-tuberculosis drugs and their serum levels (English)

1 reference

5 August 2017

1 reference

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25653488%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

Jong Sun Park

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25653488%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

Young Jae Cho

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25653488%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

Ho Il Yoon

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25653488%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

Junghan Song

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25653488%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

6

Choon-Taek Lee

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25653488%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

5 August 2017

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25653488%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

author name string

Ina Jeong

1

1 reference

5 August 2017

Jong-Sun Park

2

1 reference

5 August 2017

Young-Jae Cho

3

1 reference

5 August 2017

Ho Il Yoon

4

1 reference

5 August 2017

Junghan Song

5

1 reference

5 August 2017

Jae-Ho Lee

7

1 reference

5 August 2017

publication date

21 January 2015

1 reference

Journal of Korean Medical Science

5 August 2017

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25653488%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

volume

30

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25653488%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25653488%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

page(s)

167-172

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25653488%20AND%20SRC:MED&resulttype=core&format=json

NAT2 polymorphisms and susceptibility to anti-tuberculosis drug-induced liver injury: a meta-analysis

1 June 2020

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4310943

Incidence, clinical features and impact on anti-tuberculosis treatment of anti-tuberculosis drug induced liver injury (ATLI) in China

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4310943

Therapeutic Drug Monitoring for Slow Response to Tuberculosis Treatment in a State Control Program, Virginia, USA

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4310943

Antituberculosis drug-induced hepatotoxicity: concise up-to-date review

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4310943

Concentration-dependent Mycobacterium tuberculosis killing and prevention of resistance by rifampin

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4310943

Pharmacokinetics and tolerability of a higher rifampin dose versus the standard dose in pulmonary tuberculosis patients

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4310943

Antituberculosis drugs and hepatotoxicity

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4310943

An official ATS statement: hepatotoxicity of antituberculosis therapy

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4310943

American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4310943

Incidence of serious side effects from first-line antituberculosis drugs among patients treated for active tuberculosis

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4310943

Therapeutic drug monitoring in the treatment of tuberculosis

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4310943

Hepatotoxicity of tuberculosis chemotherapy under general programme conditions in Singapore

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4310943

Antituberculosis drug-induced hepatotoxicity. The role of hepatitis C virus and the human immunodeficiency virus

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4310943

Population pharmacokinetic modeling of isoniazid, rifampin, and pyrazinamide

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4310943

Deleterious influence of pyrazinamide on the outcome of patients with fulminant or subfulminant liver failure during antituberculous treatment including isoniazid

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4310943

Correlation of plasma anti-tuberculosis drug levels with subsequent development of hepatotoxicity

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4310943

Clinical and toxicodynamic evidence that high-dose pyrazinamide is not more hepatotoxic than the low doses currently used

25 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4310943

NAT2 and CYP2E1 polymorphisms and susceptibility to first-line anti-tuberculosis drug-induced hepatitis.

25 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4310943

Hepatotoxicity of pyrazinamide: cohort and case-control analyses

25 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4310943

Low serum concentrations of anti-tuberculosis drugs and determinants of their serum levels.

25 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4310943

The influence of dose and N-acetyltransferase-2 (NAT2) genotype and phenotype on the pharmacokinetics and pharmacodynamics of isoniazid.

25 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4310943

Antituberculosis drugs and hepatotoxicity

25 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4310943

Managing antituberculosis drug therapy by therapeutic drug monitoring of rifampicin and isoniazid

25 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4310943

Low isoniazid concentrations and outcome of tuberculosis treatment with once-weekly isoniazid and rifapentine

25 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4310943

Polymorphism of the N-acetyltransferase 2 gene as a susceptibility risk factor for antituberculosis drug-induced hepatitis

25 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4310943

Simultaneous determination of first-line anti-tuberculosis drugs and their major metabolic ratios by liquid chromatography/tandem mass spectrometry

25 October 2018

1 reference

12 December 2020

Utility of rifampin blood levels in the treatment and follow-up of active pulmonary tuberculosis in patients who were slow to respond to routine directly observed therapy

1 reference

12 December 2020

Risk factors for side-effects of isoniazid, rifampin and pyrazinamide in patients hospitalized for pulmonary tuberculosis

1 reference

12 December 2020

Low serum antimycobacterial drug levels in non-HIV-infected tuberculosis patients

1 reference

12 December 2020

10.3346/JKMS.2015.30.2.167

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25653488%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25653488%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25653488%20AND%20SRC:MED&resulttype=core&format=json